Media Articles Related to Invega (Paliperidone)
Schizophrenia's genetic 'skyline' rising - suspect common variants soar from 30 to 108
Source: Genetics News From Medical News Today [2014.07.23]
The largest genomic dragnet of any psychiatric disorder to date has unmasked 108 chromosomal sites harboring inherited variations in the genetic code linked to schizophrenia, 83 of which had not been...
Could vitamin D deficiency increase the risk of schizophrenia?
Source: Mental Health News From Medical News Today [2014.07.23]
Vitamin D deficiency has been linked to numerous health problems. Now, a new study suggests that people who are vitamin D deficient may be more likely to develop schizophrenia.
Gene Discoveries Could Shed New Light on Schizophrenia
Source: MedicineNet Schizophrenia Specialty [2014.07.23]
Title: Gene Discoveries Could Shed New Light on Schizophrenia
Category: Health News
Created: 7/22/2014 12:35:00 PM
Last Editorial Review: 7/23/2014 12:00:00 AM
New Schizophrenia Genes Identified
Source: Medscape Psychiatry & Mental Health Headlines [2014.07.22]
Eighty-three novel genes linked to schizophrenia, including one that also raises the risk for bipolar disorder and alcoholism, have been identified.
Medscape Medical News
Rare gene could increase risk of schizophrenia, alcoholism and bipolar
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.07.22]
Scientists from the UK have identified a rare gene variant associated with developing severe chronic conditions such as schizophrenia that could lead to new treatment targets.
Published Studies Related to Invega (Paliperidone)
Bilastine: in allergic rhinitis and urticaria. 
Bilastine is an orally administered, second-generation antihistamine used in the
symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and
urticaria. In two well designed phase III trials, 14 days' treatment with
bilastine was associated with a significantly lower area under the effect curve
(AUEC) for the reflective total symptom score (TSS) than placebo in patients with
symptomatic seasonal allergic rhinitis...
A randomized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients with bipolar I disorder
after an acute manic or mixed episode. 
patients with this disorder... CONCLUSIONS: Paliperidone ER significantly delayed the time to recurrence of any
Oral paliperidone: a review of its use in the management of schizoaffective disorder. [2011.06.01]
Oral paliperidone extended or prolonged release (Invega(R)) is an atypical antipsychotic, and is the first agent approved for the treatment of schizoaffective disorder. Paliperidone (or 9-hydroxyrisperidone) is the major active metabolite of the well known atypical antipsychotic risperidone, and its mechanism of action is thought to be the antagonism of dopamine D(2) and serotonin 5-HT(2A) receptors...
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. [2011.03]
BACKGROUND: Combination treatment with atypical antipsychotics and a mood stabilizer is often recommended for treatment of manic or mixed episodes associated with bipolar I disorder... CONCLUSIONS: In this study, flexibly-dosed paliperidone ER used as adjunctive therapy to mood stabilizers did not demonstrate efficacy over mood stabilizer monotherapy. No new safety signals were observed with combination treatment in this population. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011.01]
The effect of two atypical antipsychotics on QTc intervals (heart rate-corrected QT interval) was evaluated. Patients (N=109) with schizophrenia (79%) or schizoaffective disorder (21%) were randomly assigned in 2 : 2 : 1 ratio to paliperidone extended release (ER), quetiapine, or placebo... The effect on the QTc interval in patients with schizophrenia or schizoaffective disorder was comparable between paliperidone ER 12 mg/day (maximum recommended dose), paliperidone ER 18 mg/day (supratherapeutic dose), and quetiapine 800 mg/day.
Clinical Trials Related to Invega (Paliperidone)
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning [Recruiting]
The purpose of this study is to better understand brain function and psychiatric and
neurological illness when taking Invega or Risperdal. The objective is to compare the brain
effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be
evaluated with PET imaging, fMRI, and neurological ratings and assessments.
Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism [Not yet recruiting]
Our primary specific aim is to examine the efficacy of Paliperidone extended release
Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic
symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. We
hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) treated group will
have a statistically significant advantage on improvement in manic symptoms. They will also
have higher rate of treatment response and remission.
A Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia [Recruiting]
This study will explore the efficacy and safety of flexibly dosed paliperidone ER in
subjects with schizophrenia.
At the end of 12 months, flexible dose paliperidone treatment is expected to improve
functionality and satisfaction of schizophrenia patients significantly as measured by PSP.
The expected increase in PSP score is approximately 10-20%
Invega for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder [Recruiting]
This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the
treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or
Bipolar Spectrum Disorder. Specific hypotheses are as follows:
Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV
Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment.
Hypothesis 2: Invega - associated improvement in bipolar disorder symptomatology in children
and adolescents will translate into improved functional capacities (neuropsychological,
social, and occupational), as well as an increased quality of life throughout treatment.
Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop
out rate and absence of major side effects.
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia [Recruiting]
Primary objective: To examine whether the switch to paliperidone ER from risperidone
improves cognitive function in stabilized patients with schizophrenia.
Secondary objectives: To compare the general clinical outcomes (efficacy and safety) after
switching to paliperidone ER from risperidone
Reports of Suspected Invega (Paliperidone) Side Effects
Extrapyramidal Disorder (31),
Drug Ineffective (30),
Weight Increased (27),
Abnormal Behaviour (22),
Tardive Dyskinesia (22), more >>